Optimal management of digital ulcers in systemic sclerosis
Authors:
Open Access
- 1 June 2015
- journal article
- review article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 11, 939-947
Abstract
Raynaud’s phenomenon and digital ulcerations are two common clinical features seen in patients with systemic sclerosis. They are painful and lead to significant morbidity and altered hand function within this patient population. While currently there are no US Food and Drug Administration (FDA)-approved medications for the treatment of digital ulcerations in the United States, clinical trials have supported the use of pharmacologic and nonpharmacologic modalities in facilitating healing of existing digital ulcers and preventing formation of new ulcers. This article reviews the published data on these therapeutic options.Keywords
This publication has 45 references indexed in Scilit:
- Surgical treatment of systemic sclerosis—is it justified to offer peripheral sympathectomy earlier in the disease process?Microsurgery, 2015
- Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literatureAutoimmunity Reviews, 2014
- Autologous Fat Grafting for Scleroderma-Induced Digital Ulcers. An Effective Technique in Patients with Systemic SclerosisHandchirurgie · Mikrochirurgie · Plastische Chirurgie, 2014
- Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis.2009
- Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.2009
- Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factorsBritish Journal of Dermatology, 2009
- MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trialArthritis & Rheumatism, 2009
- Faculty Opinions recommendation of Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.2008
- Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis & Rheumatism, 1999
- Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind StudyAnnals of Internal Medicine, 1994